A61K 31/4365
The heterocyclic ring system having sulfur as a ring hetero atom
Official title: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K31/4365 (The heterocyclic ring system having sulfur as a ring hetero atom) appears on 470 US grants and 947 published applications in this corpus.
Search patents in A61K- Granted patents
- 470
- Published applications
- 947
- Assignees
- 498
- Inventors
- 2,247
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 0 | 0 |
| 1999 | 3 | 0 |
| 2000 | 1 | 0 |
| 2001 | 5 | 1 |
| 2002 | 4 | 7 |
| 2003 | 3 | 13 |
| 2004 | 1 | 12 |
| 2005 | 4 | 11 |
| 2006 | 7 | 12 |
| 2007 | 0 | 15 |
| 2008 | 10 | 18 |
| 2009 | 3 | 29 |
| 2010 | 4 | 35 |
| 2011 | 17 | 26 |
| 2012 | 8 | 37 |
| 2013 | 21 | 49 |
| 2014 | 28 | 49 |
| 2015 | 26 | 55 |
| 2016 | 29 | 44 |
| 2017 | 40 | 49 |
| 2018 | 34 | 44 |
| 2019 | 30 | 50 |
| 2020 | 31 | 50 |
| 2021 | 36 | 51 |
| 2022 | 22 | 55 |
| 2023 | 29 | 80 |
| 2024 | 21 | 58 |
| 2025 | 30 | 52 |
| 2026 | 19 | 45 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Bacterial DNA gyrase inhibitors and methods of use thereof25 Aug 2026US 12,714,692 B2The Florida International University Board of Trustees
- Cyclic compounds and methods of using same25 Aug 2026US 12,715,876 B2Schrödinger, Inc.
- Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease16 Jun 2026US 12,653,810 B2SHY Therapeutics LLC
- CGAS antagonist compounds16 Jun 2026US 12,655,118 B2Board of Regents, The University of Texas System
- Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 2816 Jun 2026US 12,655,155 B2Dana-Farber Cancer Institute, Inc.
- Inverse agonists of rar related orphan receptors (rors)8 Oct 2026US 2026/0306484 A111949098 CANADA INC. (NUREDCO) c/o Jean I. TCHERVENKOV
- Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks24 Sep 2026US 2026/0284017 A1Nflection Therapeutics, Inc.
- Use of milvexian in the treatment and prevention of thrombotic conditions in patients with cardiovascular or cerebrovascular disease24 Sep 2026US 2026/0284049 A1Bristol-Myers Squibb Company
- Heteroaryl derivatives as ddrs inhibitors24 Sep 2026US 2026/0285855 A1Chiesi Farmaceutici S.P. A.
- Method for treating acute ischemic stroke17 Sep 2026US 2026/0272909 A1Lumosa Therapeutics Co., Ltd.
Most cited
By later US patents
- Maintenance of platelet inhibition during antiplatelet therapy253US 10,022,391 B2Chiesi Farmaceutici S.P. A. · 2018
- Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same118US 8,835,407 B2CyDex Pharmaceuticals, Inc. · 2014
- Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof93US 8,668,926 B12014
- Modulators of cystic fibrosis transmembrane conductance regulator80US 8,399,479 B2Vertex Pharmaceuticals Incorporated · 2013
- Modulators of cystic fibrosis transmembrane conductance regulator64US 8,710,075 B2Vertex Pharmaceuticals Incorporated · 2014